| Popis: |
Heart failure (HF) is the final manifestation of various cardiovascular (CV) diseases, which has caused a huge health burden. Although great progress has been made in the treatment strategy, it still cannot solve the dilemma of HF treatment. As a sodium glucose transporter 2 inhibitor, dapagliflozin is a hypoglycemic drug. However, recent research has found that it can play a crucial role in preventing HF, regardless of whether patients have diabetes or not. There are many mechanisms involved, so this review focuses on elucidating the beneficial evidence and mechanism of dapagliflozin in treating HF, in order to provide new insights into the treatment of HF. |
